Manufacturing: Page 3


  • A photo of the production process for Eli Lilly's bamlanivimab
    Image attribution tooltip
    Courtesy of Eli Lilly
    Image attribution tooltip

    US stocks up on COVID-19 antibody drugs amid shortage concerns

    Deals with Regeneron and Eli Lilly will secure nearly 1.8 million additional doses of the companies' respective treatments over the next four months.

    By Sept. 15, 2021
  • Employees of CureVac work in a laboratory
    Image attribution tooltip
    Courtesy of CureVac
    Image attribution tooltip

    CureVac scales back mRNA manufacturing for coronavirus vaccine

    The German biotech, which announced disappointing results for its shot in June, said the move was done in response to reduced demand. 

    By Shoshana Dubnow • Updated Sept. 15, 2021
  • Resilience will manufacture mRNA for Moderna’s COVID-19 Vaccine at its facility in Mississauga, Ontario, Canada.
    Image attribution tooltip
    Courtesy of National Resilience; Business Wire
    Image attribution tooltip

    Moderna expands mRNA vaccine supply in deal with new biotech producer

    The company has previously said it could make up to 3 billion vaccine doses in 2022, depending on how booster shots are authorized.

    By Shoshana Dubnow • Sept. 8, 2021
  • Image attribution tooltip
    Maddie Meyer via Getty Images
    Image attribution tooltip

    Eyeing future outbreaks, Moderna partners with Canadian government on vaccine plant

    While Canada has already secured more COVID-19 vaccine doses than it needs, the factory to be built is geared toward combating future pandemics.

    By Aug. 10, 2021
  • An outside view of an Amgen building.
    Image attribution tooltip
    Amgen Inc.
    Image attribution tooltip

    Amgen, expecting higher demand for its medicines, to build plant in North Carolina

    The biotech is also constructing a new factory in Ohio and, between the two, expects to investment nearly $1 billion over the next few years.

    By Kristin Jensen • Aug. 4, 2021
  • The historic Mylan plant in Morgantown, West Virginia.
    Image attribution tooltip
    Permission granted by Albert Haught
    Image attribution tooltip

    A pharma merger's impact ripples across West Virginia as Viatris plant closes

    One of the country's oldest and largest drug manufacturing plants shut down Saturday, a consequence of the 2019 merger between Mylan and Pfizer's Upjohn unit. The impact will be felt by a West Virginia city for years to come.

    By Shoshana Dubnow • July 30, 2021
  • Bluebird preps for split by selling manufacturing plant to well-funded startup

    The startup manufacturing specialist National Resilience, which raised $800 million when it launched last year, will pay Bluebird $110 million for the North Carolina facility, bringing its North American network up to 10.

    By Kristin Jensen • July 29, 2021
  • The World Health Organization emblem of a snake symbol for medicine coiling around UN symbol.
    Image attribution tooltip
    Sean Gallup via Getty Images
    Image attribution tooltip

    BioNTech, WHO hatch plan to bring mRNA vaccines to Africa

    Responding to criticism, the German biotech plans to develop a malaria shot and build manufacturing infrastructure on the continent. 

    By July 26, 2021
  • Image attribution tooltip
    Permission granted by ZS
    Image attribution tooltip
    Sponsored by ZS

    Trends shaping biopharma's role in the healthcare ecosystem

    Four trends are shaping the healthcare ecosystem. These present new opportunities for biopharma.

    By Pratap Khedkar and Jude Konzelmann • July 26, 2021
  • People work in a drug research laboratory
    Image attribution tooltip
    Permission granted by Faze Medicines / Marissa Fiorucci
    Image attribution tooltip
    Sponsored by Avid Bioservices

    Unique commercial experience primes Avid Bioservices for growth

    Discover the bioservices and manufacturing efforts that have made an impact within the biological manufacturing field.

    By Nick Green, Chief Executive Officer, Avid Bioservices • June 28, 2021
  • Image attribution tooltip
    Permission granted by Emergent Biosolutions
    Image attribution tooltip
    Sponsored by Emergent Biosolutions

    Lyophilized products are on the rise: Here's what you need to know

    To extend the shelf life and improve stability of biopharmaceuticals, a freeze-drying process—and a partner—can help.

    By Kate Silver • June 14, 2021
  • UK drug contractor to be sold to private equity firm in $1.4B deal

    Through a subsidiary, The Carlyle Group will pay a 27% premium to acquire Vectura, a CDMO that specializes in inhaled medicines.

    By Kristin Jensen • May 26, 2021
  • Image attribution tooltip
    Tasos Katopodis via Getty Images
    Image attribution tooltip

    Emergent CEO defends company from criticism of error that ruined vaccine doses

    The company expects to respond within days to a long list of findings FDA officials made in an inspection of Emergent's Baltimore plant earlier this month.

    By April 30, 2021
  • Image attribution tooltip
    Maddie Meyer via Getty Images
    Image attribution tooltip

    Moderna plans to triple coronavirus vaccine production next year

    The biotech aims to double capacity at plants in Switzerland and Spain, and by 50% at U.S. sites. The total number, however, will depend on the mix of primary and booster doses.

    By April 29, 2021
  • Image attribution tooltip
    Justin Sullivan via Getty Images
    Image attribution tooltip

    Gilead, Merck to help India access COVID-19 drugs as country's crisis deepens

    Gilead will donate at least 450,000 vials of Veklury, while Merck licensed its experimental antiviral molnupiravir to five generic drugmakers in India. 

    By April 27, 2021
  • Glass vials of Moderna COVID-19 vaccine.
    Image attribution tooltip
    Gabriel Kuchta via Getty Images
    Image attribution tooltip

    Sanofi to aid Moderna on final steps in manufacturing coronavirus vaccine

    The French pharma has agreed to "fill and finish" up to 200 million vials of Moderna's shot at its New Jersey plant, the third such manufacturing deal it struck with other vaccine developers. 

    By April 26, 2021
  • Image attribution tooltip
    Tasos Katopodis via Getty Images
    Image attribution tooltip

    FDA cites Emergent for failings at plant that contaminated J&J doses

    A recent nine-day inspection by agency officials found numerous breaches of manufacturing standards and inadequate training for factory employees. 

    By April 22, 2021
  • A still of COVID-19 vaccine vials from Johnson & Johnson going through production
    Image attribution tooltip
    Permission granted by Johnson & Johnson
    Image attribution tooltip

    J&J to oversee vaccine production at Emergent factory that ruined doses

    The change, which follows the contractor's costly manufacturing mix-up, will displace production of AstraZeneca's unauthorized shot at the Baltimore site.

    By April 5, 2021
  • A still of COVID-19 vaccine vials from Johnson & Johnson going through production
    Image attribution tooltip
    Permission granted by Johnson & Johnson
    Image attribution tooltip

    Manufacturing mix-up could blunt supply boost from J&J vaccine

    One vaccine batch being manufactured for J&J by Emergent Biosolutions failed quality checks, reportedly ruining material sufficient for up to 15 million doses. 

    By April 1, 2021
  • Image attribution tooltip
    Rawf8 via Getty Images
    Image attribution tooltip
    Sponsored by Reed Tech

    How to navigate Health Canada XML PM requirements

    Learn the latest about XML PM mandates and timelines from structured labeling experts.

    March 22, 2021
  • Image attribution tooltip
    DragonImages via Getty Images
    Image attribution tooltip
    Sponsored by Millipore-Sigma®

    Paving the way towards the biomanufacturing facility of the future

    Technologies that enable bioprocessing 4.0 are creating the roadmap to the facility of the future.

    By Merrilee Whitney, Head of the BioContinuum™ platform • March 15, 2021
  • A still of COVID-19 vaccine vials from Johnson & Johnson going through production
    Image attribution tooltip
    Permission granted by Johnson & Johnson
    Image attribution tooltip

    Vaccine factories churn out millions more doses, speeding US rollout of coronavirus shots

    The U.S. is now averaging more than 2 million doses given each day, a pace that will help President Joe Biden meet his target of 100 million shots in 100 days well ahead of schedule. 

    By March 11, 2021
  • Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Merck to help J&J make vaccine doses in White House-brokered deal

    The U.S. government will give Merck $269 million to help the drugmaker retool two of its facilities to make J&J's one-dose shot. 

    By Updated March 2, 2021
  • Image attribution tooltip
    Moderna
    Image attribution tooltip

    Moderna, Pfizer ready multi-pronged plans for coronavirus variants

    Moderna has delivered a modified version of its vaccine to NIH scientists, while Pfizer has begun testing of an additional booster shot in a clinical trial, both precautionary steps against emerging strains.

    By , Updated Feb. 25, 2021
  • Pfizer set to double weekly production of coronavirus vaccine

    The drugmaker will use production lines at its plant in McPherson, Kansas to help fill vaccine vials, company CEO Albert Bourla said Friday.

    By Feb. 19, 2021